CELZ News & Events

Creative Medical Technology announced the transition of Project PHOENIX, its proprietary veteran support registry and biodefense initiative, into its nationwide virtual data collection phase. Designed for veterans exposed to burn pits and toxic environmental hazards, the program is engineered to scale to a cohort of at least 1,000 participants using mobile-application data collection and field-capable logistics. The accumulated data will support the development of the CELZ-Biodefense Toxic Exposure Atlas to aid in drug, biologic, and regenerative therapy discovery. Creative Medical expects the current initiative to be executed through existing infrastructure, previously developed intellectual property, internal capabilities and established vendor relationships, and does not currently expect the initiative to require additional fundraising.

Creative Medical announced results from its pilot study of Ultrasome, the company's cell-free regenerative therapy for the treatment of osteoarthritis of the knee. The study achieved its primary endpoint with 93% of patients demonstrating clinically meaningful improvements in mobility and pain reduction, with the therapy well-tolerated and no serious adverse events reported. Ultrasome is derived from the company's GMP-manufactured cell therapy product CELZ-201, which is currently being evaluated in the company's FDA-cleared ADAPT clinical trial. The company said this relationship establishes a direct connection between CELZ's clinical-stage biologic platform and its next-generation cell-free regenerative strategy, expanding the potential applications of CELZ-201 into broader, high-volume indications.